Major European regulatory milestone in cardiovascular protection for Micardisreg; (telmisartan): Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients
Closely following FDA approval, Micardisreg; is now indicated by the European Commission for the reduction of CV morbidity in patients with manifest atherothrombotic CV disease or type 2 diabetes with documented target organ damage. Micardisreg; (telmisartan) is the ONLY treatment in its class with this indication, demonstrating proven cardiovascular (CV) protection in patients at high CV risk This new indication is based on a review of clinical trials, including results from the ONTARGET trial, which showed that Micardisreg; may prevent one in five serious CV events1Patients at-risk of heart attack and stroke can now benefit from this new indication. Ingelheim/Germany, 26 November 2009 - Boehringer Ingelheim announced today that the European Commission has approved Micardisreg; ...

Study indicates that induced labor may not lower risk of infection or respiratory problems in newborns
(Society for Maternal-Fetal Medicine) In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, the Pregnancy Meeting, in Dallas, Texas, researchers will report findings that suggest that induction of labor in patients who suffer a rupture of membranes between the 34th and 37th week of gestation (before the onset of labor) does not reduce the risk of infection or respiratory problems in the newborn. (Source: EurekAlert! - Medicine and Health)